BELLEVUE, WA, Jan. 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ:ONTY, TSX:ONY) today announced that it has received a letter from The NasdaqStock Market, indicating that the Company has regained compliance with the$1.00 per share minimum closing bid price requirement for continued listing onthe Nasdaq Global Market, pursuant to Nasdaq Marketplace Rule 4450(a)(5). Inthe letter, Nasdaq advised the Company that this matter is now closed.
Oncothyreon is a biotechnology company specializing in the development ofinnovative therapeutic products for the treatment of cancer. Oncothyreon'sgoal is to develop and commercialize novel synthetic vaccines and targetedsmall molecules that have the potential to improve the lives and outcomes ofcancer patients. For more information visit www.oncothyreon.com.
SOURCE Oncothyreon Inc.